Abstract
Cordis Corporation recently announced that it has received CE mark approval for the treatment of acute myocardial infarction (AMI) using the CYPHER® SELECT™ PLUS sirolimus-eluting coronary stent. CE marking means conformity to the applicable European Directive, and in the specific context of AMI permits the CYPHER stent to be placed on the market for treatment of AMI in all Member States of the EU, the European Economic Area and Switzerland.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
